Branch Retinal Vein Occlusion
Conditions
Interventions
Micropulse laser combined with ralizumab group:Three vitreous injections of 0.5 mg of ralizumab were combined with micropulsed laser therapy/remedial ralizumab injection
Pure rabizumab group:Vitreous injection of remizumab 0.5 mg PRN based on vision stability criteria
Sponsors
Beijing Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 80 Years
Inclusion criteria
Inclusion criteria: 1.Before performing any research-related evaluation, voluntarily sign an informed consent form; 2.Adult males or females aged >= 18 and = 24 and 250um; Contralateral eye 6.At the time of screening, the BCVA of the contralateral eye >= 34 ETDRS letters and no obvious BRVO lesions.
Exclusion criteria
Exclusion criteria: 1.Failure to follow research or follow-up procedures; 2.Pregnant or lactating women and women who are likely to give birth without effective contraception; 3.History of stroke or myocardial infarction within 3 months before screening visit; 4.Renal failure or creatinine level > 2.0 mg/dL; 5.Uncontrolled hypertension; 6.Any active ocular infection or intraocular inflammation; 7.Iris neovascularization or neovascular glaucoma in either eye; 8.Uveitis or vitreous macular traction, history of macular epiretinal membrane in any eye; 9.Any eye was treated with anti-VEGF drugs within 3 months before the baseline visit; 10.Study eyes with glaucoma or IOP >= 24 mmHg; 11.Study eyes with diabetic retinopathy; 12.Other experimental drugs were used within 30 days before the baseline visit, and systemic anti-VEGF drugs were used within 6 months before the baseline visit; 13.Within 3 months before the baseline, the study eyes had undergone micropulse laser photocoagulation or intraocular surgery; 14.Phakic study eyes and aphakic or intraocular lens eyes (within 3 months before screening) have a history of intravitreal corticosteroid therapy; 15.The history of vitrectomy in study eyes.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Best corrected visual acuity; | — |
Secondary
| Measure | Time frame |
|---|---|
| Central retinal thickness; | — |
Countries
China
Contacts
Public ContactSong Shuang
Beijing Hospital
Outcome results
None listed